JP5846717B2 - パロキセチンによる体温調節機能障害の治療方法 - Google Patents
パロキセチンによる体温調節機能障害の治療方法 Download PDFInfo
- Publication number
- JP5846717B2 JP5846717B2 JP2009522831A JP2009522831A JP5846717B2 JP 5846717 B2 JP5846717 B2 JP 5846717B2 JP 2009522831 A JP2009522831 A JP 2009522831A JP 2009522831 A JP2009522831 A JP 2009522831A JP 5846717 B2 JP5846717 B2 JP 5846717B2
- Authority
- JP
- Japan
- Prior art keywords
- paroxetine
- pharmaceutical composition
- day
- treatment
- menopause
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims description 47
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims description 40
- 229960002296 paroxetine Drugs 0.000 title claims description 39
- 230000001331 thermoregulatory effect Effects 0.000 title claims description 15
- 230000004064 dysfunction Effects 0.000 title claims description 12
- 238000011282 treatment Methods 0.000 title description 19
- 206010060800 Hot flush Diseases 0.000 claims description 31
- 208000033830 Hot Flashes Diseases 0.000 claims description 20
- 230000009245 menopause Effects 0.000 claims description 15
- 239000012458 free base Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010029410 night sweats Diseases 0.000 claims description 5
- 230000036565 night sweats Effects 0.000 claims description 5
- 229960005183 paroxetine hydrochloride Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- SHIJTGJXUHTGGZ-RVXRQPKJSA-N (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidin-1-ium;methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 SHIJTGJXUHTGGZ-RVXRQPKJSA-N 0.000 claims 1
- 229960002567 paroxetine mesylate Drugs 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 11
- 239000000935 antidepressant agent Substances 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 10
- 230000001430 anti-depressive effect Effects 0.000 description 9
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010016825 Flushing Diseases 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 229960002073 sertraline Drugs 0.000 description 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- -1 anhydrous forms Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 230000001457 vasomotor Effects 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000003698 Heroin Dependence Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
- 150000002871 norepinephrines Chemical class 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- AEIUZSKXSWGSRU-QXGDPHCHSA-N paroxetine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AEIUZSKXSWGSRU-QXGDPHCHSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/499,586 | 2006-08-04 | ||
| US11/499,586 US20080033050A1 (en) | 2006-08-04 | 2006-08-04 | Method of treating thermoregulatory disfunction with paroxetine |
| PCT/US2007/017062 WO2008019010A2 (en) | 2006-08-04 | 2007-07-31 | Method of treating thermoregulatory disfunction with paroxetine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014021171A Division JP5895009B2 (ja) | 2006-08-04 | 2014-02-06 | パロキセチンによる体温調節機能障害の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009545593A JP2009545593A (ja) | 2009-12-24 |
| JP2009545593A5 JP2009545593A5 (https=) | 2010-09-16 |
| JP5846717B2 true JP5846717B2 (ja) | 2016-01-20 |
Family
ID=39030027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522831A Expired - Fee Related JP5846717B2 (ja) | 2006-08-04 | 2007-07-31 | パロキセチンによる体温調節機能障害の治療方法 |
| JP2014021171A Expired - Fee Related JP5895009B2 (ja) | 2006-08-04 | 2014-02-06 | パロキセチンによる体温調節機能障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014021171A Expired - Fee Related JP5895009B2 (ja) | 2006-08-04 | 2014-02-06 | パロキセチンによる体温調節機能障害の治療方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US20080033050A1 (https=) |
| EP (2) | EP2068881B1 (https=) |
| JP (2) | JP5846717B2 (https=) |
| KR (3) | KR20140098865A (https=) |
| CN (1) | CN101505759A (https=) |
| AU (1) | AU2007282065B2 (https=) |
| BR (1) | BRPI0715087A2 (https=) |
| CA (1) | CA2659577C (https=) |
| CY (2) | CY1120867T1 (https=) |
| DK (2) | DK2068881T3 (https=) |
| ES (2) | ES2698207T3 (https=) |
| HR (2) | HRP20181893T1 (https=) |
| HU (2) | HUE040099T2 (https=) |
| IL (1) | IL196844A (https=) |
| LT (2) | LT2719385T (https=) |
| ME (1) | ME00592B (https=) |
| MX (1) | MX2009001275A (https=) |
| NO (1) | NO343176B1 (https=) |
| NZ (1) | NZ574735A (https=) |
| PL (2) | PL2719385T3 (https=) |
| PT (2) | PT2068881T (https=) |
| RS (2) | RS58046B1 (https=) |
| RU (1) | RU2478379C2 (https=) |
| SG (1) | SG176452A1 (https=) |
| SI (2) | SI2719385T1 (https=) |
| UA (1) | UA96770C2 (https=) |
| WO (1) | WO2008019010A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080033050A1 (en) | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
| US9211290B2 (en) * | 2012-12-31 | 2015-12-15 | Noven Therapeutics, Llc | Solid dispersions of amorphous paroxetine mesylate |
| CN107249615B (zh) * | 2015-04-07 | 2021-02-05 | 株式会社明治 | 潮热抑制剂 |
| KR102817311B1 (ko) | 2016-09-29 | 2025-06-09 | (주)아모레퍼시픽 | 젖산을 유효성분으로 포함하는 열성홍조 개선용 건강식품 조성물 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| GB8520154D0 (en) * | 1985-08-10 | 1985-09-18 | Beecham Group Plc | Chemical process |
| EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
| GB8714707D0 (en) * | 1987-06-23 | 1987-07-29 | Beecham Group Plc | Chemical process |
| GB9325644D0 (en) * | 1993-12-15 | 1994-02-16 | Smithkline Beecham Plc | Novel formulation |
| US5470846A (en) * | 1994-01-14 | 1995-11-28 | Sandyk; Reuven | Treatment of neurological and mental disorders |
| JPH0837567A (ja) | 1994-07-26 | 1996-02-06 | Olympus Optical Co Ltd | 情報記録媒体及び情報再生装置 |
| US5856493A (en) * | 1995-02-06 | 1999-01-05 | Smithkline Beecham Corporation | Process for making novel form of paroxeting hydrochloride anhydrate |
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| US6548084B2 (en) * | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| JP3882224B2 (ja) * | 1996-05-31 | 2007-02-14 | 旭硝子株式会社 | パロキセチンの製造方法 |
| US6638948B1 (en) | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| US5672612A (en) * | 1996-09-09 | 1997-09-30 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| CA2193939C (en) * | 1996-12-24 | 2002-02-12 | K.S. Keshava Murthy | Useful form of anhydrous paroxetine hydrochloride |
| GB9700690D0 (en) * | 1997-01-15 | 1997-03-05 | Smithkline Beecham Plc | Novel process |
| GB9710004D0 (en) * | 1997-05-17 | 1997-07-09 | Knoll Ag | Chemical process |
| US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| BR9809687A (pt) * | 1997-05-29 | 2000-07-11 | Smithkline Beecham Corp | Processo novo |
| AU3108097A (en) * | 1997-06-10 | 1998-12-30 | Synthon B.V. | 4-phenylpiperidine compounds |
| US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
| SE9900190D0 (sv) * | 1999-01-22 | 1999-01-22 | Astra Ab | New compounds |
| SE9702799D0 (sv) * | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
| US6133277A (en) * | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| EA200000890A1 (ru) | 1998-03-02 | 2001-02-26 | Эли Лилли Энд Компани | Гидрохлорид флуоксетина для уменьшения "приливов" (приступообразных ощущений жара (при климактерическом синдроме)) |
| PL342931A1 (en) | 1998-03-16 | 2001-07-16 | Smithkline Beecham Plc | Crystalline form of paroxetine |
| US6699882B2 (en) * | 1998-03-24 | 2004-03-02 | Smithkline Beecham P.L.C. | Paroxetine compositions |
| US20030028027A1 (en) * | 1998-04-09 | 2003-02-06 | Smithkline Beecham Plc | Paroxetine maleate |
| JP3796351B2 (ja) * | 1998-04-13 | 2006-07-12 | 住友化学株式会社 | パロキセチン塩酸塩無水和物の乾燥方法 |
| US6168805B1 (en) * | 1998-05-07 | 2001-01-02 | Endo Pharmaceuticals, Inc. | Aqueous process for manufacturing paroxetine solid dispersions |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| ES2138937B1 (es) * | 1998-07-07 | 2000-10-01 | Medichem Sa | Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen. |
| ES2159260B1 (es) * | 1999-06-22 | 2002-05-01 | Smithkline Beechan Plc | Nueva composicion de metanosulfonato de paroxetina |
| US6369051B1 (en) * | 2000-07-06 | 2002-04-09 | American Home Products Corporation | Combinations of SSRI and estrogenic agents |
| US6660298B1 (en) * | 2000-07-27 | 2003-12-09 | Pentech Pharmaceuticals, Inc. | Paroxetine tablets and capsules |
| CA2418038A1 (en) | 2000-08-28 | 2002-03-07 | Synthon B.V. | Paroxetine compositions and processes for making the same |
| US6498184B2 (en) * | 2000-12-05 | 2002-12-24 | Akzo Nobel N.V. | Serotonergic compound for a method of treatment of hot flushes in post-menopausal women |
| NZ526874A (en) * | 2001-01-04 | 2005-07-29 | Ferrer Internacional S | Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine |
| DE20100529U1 (de) | 2001-01-11 | 2001-05-10 | Synthon Bv | Pharmazeutische Tablette umfassend Paroxetinmesylat |
| NL1017421C2 (nl) * | 2001-02-21 | 2002-01-15 | Synthon Bv | Werkwijze voor het vervaardigen van paroxetine. |
| EP1266659A1 (en) | 2001-06-11 | 2002-12-18 | Pantarhei Bioscience B.V. | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes |
| US6956121B2 (en) * | 2002-03-01 | 2005-10-18 | Teva Pharmaceutical Industries Ltd. | Preparation of paroxetine involving novel intermediates |
| EP1530476A1 (en) * | 2002-08-14 | 2005-05-18 | Pharmacia & Upjohn Company LLC | Use of reboxetine for the treatment of hot flashes |
| US20040152710A1 (en) | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| ITMI20022344A1 (it) * | 2002-11-05 | 2004-05-06 | Biofarm Srl | Prodotto in pellicola a rapida dissoluzione in acqua, per il trattamento del latte con batteri e/o enzimi. |
| TWI267838B (en) * | 2003-01-03 | 2006-12-01 | Lite On It Corp | Method to detect the type of optical disk |
| US20050130987A1 (en) | 2003-10-14 | 2005-06-16 | Wyeth | Methods of treating vasomotor symptoms |
| RU2007102292A (ru) * | 2004-07-22 | 2008-08-27 | Вайет (Us) | Способ лечения расстройств и заболеваний нервной системы |
| MX2007000851A (es) * | 2004-07-22 | 2007-03-26 | Wyeth Corp | Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso. |
| US20060100263A1 (en) * | 2004-11-05 | 2006-05-11 | Anthony Basile | Antipyretic compositions and methods |
| KR100764679B1 (ko) | 2005-07-22 | 2007-10-09 | 익수제약 주식회사 | 파록세틴을 함유하는 경피투여용 패취제 |
| CN101325944B (zh) * | 2005-10-11 | 2013-01-16 | 耶路撒冷希伯来大学伊萨姆研究开发公司 | 用于鼻部给药的组合物 |
| US20080033050A1 (en) | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
-
2006
- 2006-08-04 US US11/499,586 patent/US20080033050A1/en not_active Abandoned
-
2007
- 2007-07-31 SI SI200732079T patent/SI2719385T1/sl unknown
- 2007-07-31 HU HUE13190594A patent/HUE040099T2/hu unknown
- 2007-07-31 BR BRPI0715087-3A2A patent/BRPI0715087A2/pt not_active Application Discontinuation
- 2007-07-31 HR HRP20181893TT patent/HRP20181893T1/hr unknown
- 2007-07-31 EP EP07810919.6A patent/EP2068881B1/en active Active
- 2007-07-31 DK DK07810919.6T patent/DK2068881T3/en active
- 2007-07-31 MX MX2009001275A patent/MX2009001275A/es unknown
- 2007-07-31 PL PL13190594T patent/PL2719385T3/pl unknown
- 2007-07-31 AU AU2007282065A patent/AU2007282065B2/en not_active Ceased
- 2007-07-31 LT LTEP13190594.5T patent/LT2719385T/lt unknown
- 2007-07-31 LT LTEP07810919.6T patent/LT2068881T/lt unknown
- 2007-07-31 HU HUE07810919A patent/HUE040481T2/hu unknown
- 2007-07-31 PT PT07810919T patent/PT2068881T/pt unknown
- 2007-07-31 CN CNA2007800289306A patent/CN101505759A/zh active Pending
- 2007-07-31 CA CA2659577A patent/CA2659577C/en active Active
- 2007-07-31 RU RU2009107739/15A patent/RU2478379C2/ru not_active IP Right Cessation
- 2007-07-31 PL PL07810919T patent/PL2068881T3/pl unknown
- 2007-07-31 UA UAA200901871A patent/UA96770C2/uk unknown
- 2007-07-31 JP JP2009522831A patent/JP5846717B2/ja not_active Expired - Fee Related
- 2007-07-31 KR KR1020147020772A patent/KR20140098865A/ko not_active Ceased
- 2007-07-31 DK DK13190594.5T patent/DK2719385T3/en active
- 2007-07-31 KR KR1020097004195A patent/KR20090040453A/ko not_active Ceased
- 2007-07-31 KR KR1020157032729A patent/KR20150132888A/ko not_active Ceased
- 2007-07-31 ME MEP-2009-37A patent/ME00592B/me unknown
- 2007-07-31 RS RS20181386A patent/RS58046B1/sr unknown
- 2007-07-31 NZ NZ574735A patent/NZ574735A/en not_active IP Right Cessation
- 2007-07-31 ES ES07810919T patent/ES2698207T3/es active Active
- 2007-07-31 SG SG2011081056A patent/SG176452A1/en unknown
- 2007-07-31 SI SI200732071T patent/SI2068881T1/sl unknown
- 2007-07-31 ES ES13190594T patent/ES2699298T3/es active Active
- 2007-07-31 PT PT13190594T patent/PT2719385T/pt unknown
- 2007-07-31 EP EP13190594.5A patent/EP2719385B1/en active Active
- 2007-07-31 RS RS20181413A patent/RS57980B1/sr unknown
- 2007-07-31 WO PCT/US2007/017062 patent/WO2008019010A2/en not_active Ceased
-
2008
- 2008-12-01 US US12/292,960 patent/US8658663B2/en active Active
-
2009
- 2009-02-02 IL IL196844A patent/IL196844A/en active IP Right Grant
- 2009-02-10 NO NO20090639A patent/NO343176B1/no not_active IP Right Cessation
-
2014
- 2014-01-17 US US14/157,992 patent/US8946251B2/en active Active
- 2014-02-06 JP JP2014021171A patent/JP5895009B2/ja not_active Expired - Fee Related
- 2014-05-13 US US14/276,494 patent/US8859576B2/en active Active
- 2014-12-19 US US14/577,227 patent/US9393237B2/en active Active
-
2016
- 2016-07-15 US US15/211,074 patent/US20170165251A1/en not_active Abandoned
-
2017
- 2017-10-17 US US15/785,769 patent/US20200268733A9/en not_active Abandoned
-
2018
- 2018-11-19 CY CY181101219T patent/CY1120867T1/el unknown
- 2018-11-19 HR HRP20181925TT patent/HRP20181925T1/hr unknown
- 2018-11-23 CY CY181101241T patent/CY1120902T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2195093C (en) | Use of droloxifene for the treatment of prostatic diseases, endometriosis and obesity | |
| JP5895009B2 (ja) | パロキセチンによる体温調節機能障害の治療方法 | |
| JP2022521683A (ja) | 過剰増殖性疾患の治療における使用のためのａｔｒキナーゼ阻害剤ｂａｙ１８９５３４４ | |
| TW201400121A (zh) | 治療婦科疾病之組合物 | |
| JP2005531575A (ja) | チボロンおよびｓｅｒｍを含む、乳癌患者における後−閉経期障害の治療 | |
| JP2010539130A (ja) | 血管運動症状の治療 | |
| TW201707708A (zh) | 選擇性黃體酮受體調節劑（ｓｐｒｍ）療法 | |
| HK1196291A (en) | Method of treating thermoregulatory disfunction with paroxetine | |
| WO2008060397A2 (en) | Method of treating thermoregulatory disfunction | |
| CN1705475A (zh) | 通过具有去甲肾上腺素重摄取抑制剂活性和5－ht2a拮抗活性的化合物治疗血管舒缩症的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100728 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121009 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121211 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121218 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140305 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140325 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140530 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150929 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151124 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5846717 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |